LANDINE MICHAEL J

SEC source: 0001127602-24-007141 · form4.xml · derivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,233

Underlying: Ordinary Shares · 4,077 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-007141 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,730

SEC source: 0001127602-24-007141 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 283,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-006571 · form4.xml · derivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,655

Underlying: Ordinary Shares · 5,654 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-006571 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 279,464

SEC source: 0001127602-24-006571 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,393

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 20

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 5,461 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-006173 · form4.xml · nonDerivative · entry 4

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 275,739

SEC source: 0001127602-24-006173 · form4.xml · nonDerivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,345

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 19

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,897

Underlying: Ordinary Shares · 4,448 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F9 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F9 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-006173 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,884

SEC source: 0001127602-24-006173 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,192

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-24-004631 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 268,744

SEC source: 0001127602-24-004631 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 271,927

F1 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 22, 2021 with a three-year performance period that ended on December 31, 2023 (the "2021 PRSUs"). The vesting of this portion of the 2021 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2021 PRSUs.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 18

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,310

Underlying: Ordinary Shares · 319 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F11 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F11 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 17

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,241

Underlying: Ordinary Shares · 1,279 shares

Expires 2033-02-23

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F10 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 16

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,345

Underlying: Ordinary Shares · 261 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F9 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F9 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 15

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,171

Underlying: Ordinary Shares · 1,394 shares

Expires 2032-02-18

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F8 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 14

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,309

Underlying: Ordinary Shares · 221 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F7 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F7 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 13

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,296

Underlying: Ordinary Shares · 1,809 shares

Expires 2031-02-22

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F6 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 12

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,461

Underlying: Ordinary Shares · 107 shares

Expires not disclosed

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F5 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 11

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 91,335

Underlying: Ordinary Shares · 1,790 shares

Expires 2030-02-20

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F4 · derivative.exercise_date: Shares subject to the stock option award vest and become exercisable in four equal annual installments commencing on 2/20/2021.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 10

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,411

Underlying: Ordinary Shares · 1,811 shares

Expires 2029-02-21

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 9

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,589

Underlying: Ordinary Shares · 1,089 shares

Expires 2028-02-16

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 8

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,999

Underlying: Ordinary Shares · 999 shares

Expires 2027-02-17

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 7

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 77,519

Underlying: Ordinary Shares · 1,519 shares

Expires 2026-02-28

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 6

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,879

Underlying: Ordinary Shares · 879 shares

Expires 2025-02-26

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-24-006173 · form4.xml · derivative · entry 5

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,999

Underlying: Ordinary Shares · 999 shares

Expires 2024-03-03

F2 · security: Represents an equity award granted prior to the separation of the issuer's oncology business into Mural Oncology plc (the "Separation"), as adjusted on November 17, 2023 in connection with the Separation (in order to preserve the value associated with the original award) based on the equity adjustment terms set forth in the Employee Matters Agreement filed by the issuer as Exhibit 10.2 to its Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on November 15, 2023. The exercise price (if any) of the adjusted award is shown in Boxes 2 and 8, the number of shares subject to the adjusted award is shown in Box 9 and the number of shares added to the award pursuant to the adjustment is shown in Box 5.

F3 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-23-007182 · form4.xml · derivative · entry 5

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,991

Underlying: Ordinary Shares · 15,991 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/23/2024.

SEC source: 0001127602-23-007182 · form4.xml · derivative · entry 4

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,962

Underlying: Ordinary Shares · 63,962 shares

Expires 2033-02-23

F3 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.

SEC source: 0001127602-23-007182 · form4.xml · derivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,088

Underlying: Ordinary Shares · 5,544 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/22/2022.

SEC source: 0001127602-23-007182 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 250,442

SEC source: 0001127602-23-007182 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 252,904

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006515 · form4.xml · derivative · entry 11

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 5,825 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F5 · derivative.exercise_date: This award is fully vested in accordance with its terms.

F5 · derivative.expiration_date: This award is fully vested in accordance with its terms.

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 8

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,360

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 7

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,947

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006515 · form4.xml · derivative · entry 10

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,354

Underlying: Ordinary Shares · 5,354 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F4 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

F4 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/20/2021.

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 6

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 244,122

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 5

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 249,348

F2 · price: These ordinary shares were acquired by the reporting person as a result of the vesting of performance-vesting restricted stock unit awards granted to the reporting person on February 20, 2020 with a three-year performance period that ended on December 31, 2022 (the "2020 PRSUs"). The vesting of this portion of the 2020 PRSUs was triggered by the determination of achievement of certain pre-specified performance goals and application of a total shareholder return modifier and represents the final vesting event under the 2020 PRSUs.

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 4

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,578

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 239,956

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-23-006515 · form4.xml · derivative · entry 9

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,084

Underlying: Ordinary Shares · 4,361 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 2/18/2023.

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 234,602

SEC source: 0001127602-23-006515 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 236,667

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share.

SEC source: 0001127602-22-015106 · form4.xml · derivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 50,000 shares

Expires 2022-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-22-015106 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,306

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.80 to $29.46. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-22-015106 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 282,306

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001127602-22-014262 · form4.xml · derivative · entry 3

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Ordinary Shares · 25,000 shares

Expires 2022-05-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · derivative.exercise_date: These options are fully vested in accordance with their terms.

SEC source: 0001127602-22-014262 · form4.xml · nonDerivative · entry 2

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 232,306

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.95 to $27.60. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.

SEC source: 0001127602-22-014262 · form4.xml · nonDerivative · entry 1

LANDINE MICHAEL J · CIK 0001235600 · SVP, Corp Dev., Alkermes, Inc.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 257,306

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.